Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 219

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Ursodeoxycholic Acid for Liver Disease Associated With Cystic Fibrosis: A Double–Blind Multicenter Trial

Colombo, C, Battezzati, P M, Podda, M, Bettinardi, N, Giunta, A·1996·Hepatology

Abstract

Liver disease is increasingly recognized as a major cause of morbidity in cystic fibrosis (CF). Preliminary data suggest that ursodeoxycholic acid (UDCA) may be beneficial for treatment of this manifestation. We performed a double–blind, multicenter trial in these patients to establish efficacy and safety of UDCA in terms of the improvement of clinical and nutritional indicators besides standard liver function tests. We also intended to establish whether taurine supplementation has a beneficial effect in patients receiving UDCA. From June to December 1990, we enrolled in 12 centers 55 CF patients with liver disease (39 male subjects; median age, 13.8 years). They were randomly assigned to receive for 1 year one of the following treatments: UDCA (15 mg/kg body weight daily) plus taurine (30 mg/kg body weight daily), UDCA plus placebo, placebo plus taurine, or double placebo. Clinical and laboratory evaluations were performed every 3 months. After 1 year, deterioration of overall clinical conditions, as indicated by the Shwachman–Kulczycki score (SKS), occurred in patients who received placebo but not in those who received UDCA ( P = .025). Patients treated with UDCA also showed an improvement in γ–glutamyl transpeptidase (GGT) ( P = .004) and 5′–nucleotidase ( P = .006) levels. Treatment with taurine was followed by a significant increase in serum prealbumin levels ( P = .053), a trend toward a reduction in fat malabsorption, and no effect on the biochemical profile. No severe side effects occurred with any treatment. Thus, we concluded that UDCA administration improves clinical and biochemical parameters in CF patients with liver disease. Taurine supplementation may be indicated in patients with severe pancreatic insufficiency and poor nutritional status.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/hep.510230627

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 219

Metadata

Authors
Colombo, C., Battezzati, P. M., Podda, M., Bettinardi, N., & Giunta, A.
Venue
Hepatology
Published
1996-06
Volume
23
Issue
6
Pages
1484-1490
ISSN
0270-9139 (ISSN-L)
OpenAlex
W2072193478
Cited by
219
References
1
FWCI
12.17
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ursodeoxycholic Acid for Liver Disease Associated With Cystic Fibrosis: A Double–Blind Multicenter Trial. https://app.cochat.ai/papers/10.1002/hep.510230627
The paper
Colombo, C., Battezzati, P. M., Podda, M., Bettinardi, N., & Giunta, A. (1996). Ursodeoxycholic Acid for Liver Disease Associated With Cystic Fibrosis: A Double–Blind Multicenter Trial. Hepatology. https://doi.org/10.1002/hep.510230627

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.